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Background: Low plasma high-density lipoprotein cholesterol (HDL-C) levels are a strong, independent, but poorly
understood risk factor for cardiovascular disease (CVD). Although this atherogenic lipid abnormality has been widely
reported in Australia’s Indigenous peoples, Aboriginal and Torres Strait Islanders, the evidence has not come under
systematic review. This review therefore examines published data for Indigenous Australians reporting 1) mean
HDL-C levels for both sexes and 2) factors associated with low HDL-C.
Methods: PubMed, Medline and Informit ATSI Health databases were systematically searched between 1950 and
2012 for studies on Indigenous Australians reporting mean HDL-C levels in both sexes. Retrieved studies were
evaluated by standard criteria. Low HDL-C was defined as: <1.0 mmol/L. Analyses of primary data associating
measures of HDL-C with other CVD risk factors were also performed.
Results: Fifteen of 93 retrieved studies were identified for inclusion. These provided 58 mean HDL-C levels; 29 for
each sex, most obtained in rural/regional (20%) or remote settings (60%) and including 51–1641 participants. For
Australian Aborigines, mean HDL-C values ranged between 0.81-1.50 mmol/L in females and 0.76-1.60 mmol/L in
males. Two of 15 studies reported HDL-C levels for Torres Strait Islander populations, mean HDL-C: 1.00 or
1.11 mmol/L for females and 1.01 or 1.13 mmol/L for males. Low HDL-C was observed only in rural/regional and
remote settings - not in national or urban studies (n = 3) in either gender. Diabetes prevalence, mean/median
waist-to-hip ratio and circulating C-reactive protein levels were negatively associated with HDL-C levels (all P < 0.05).
Thirty-four per cent of studies reported lower mean HDL-C levels in females than in males.
Conclusions: Very low mean HDL-C levels are common in Australian Indigenous populations living in rural and remote
communities. Inverse associations between HDL-C and central obesity, diabetes prevalence and inflammatory
markers suggest a particularly adverse CVD risk factor profile. An absence of sex dichotomy in HDL-C levels
warrants further investigation.
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Preventable chronic disease, including cardiovascular
disease (CVD) and type 2 diabetes, accounts for 70% of
the difference of burden of disease between Indigenous
and broader Australian populations, and is now regarded
as one of the greatest causes of current inequities in
Indigenous health status [1]. CVD risk factors have been
consistently shown to be more pronounced in Indigen-
ous populations and include much higher rates of type 2
diabetes, cigarette smoking, overweight/obesity, alcohol
misuse, poor nutrition, depression [2], and the Metabolic
Syndrome (MetS), a cluster of various CVD and diabetes
risk factors [3,4]. Alongside this burden of preventable
non-communicable disease, high rates of infectious
disease represent an important cause of morbidity and
mortality in Indigenous Australians compared to the
broader population [5-10].
One critical aspect of this adverse CVD risk factor pro-
file is the high prevalence of low high-density lipoprotein
cholesterol (HDL-C). A low HDL-C level is strongly and
inversely associated with risk for coronary heart disease
[11]. High HDL-C exerts its cardio-protective effect pri-
marily through its role in reverse cholesterol transport
and its anti-inflammatory, anti-thrombotic and anti-
oxidative properties. As endogenous oestrogens have a
favorable effect on lipid metabolism, females often have
higher HDL-C levels than males [12]. Also, alcohol con-
sumption can increase HDL-C levels. Various metabolic
and environmental factors, including the presence of acute
or chronic infection, a high intake of refined carbohydrate
and cigarette smoking, can decrease HDL-C levels. Im-
portantly, low HDL-C is likely to be a secondary effect
from components of the MetS: insulin resistance, central
obesity, high triglyceride dyslipidaemia and chronic,
low-grade inflammation [13]. To date, no specific clin-
ical targets for HDL-C levels have been determined;
thus low HDL-C has been variously defined [14-19]. In
Australia, lipid management guidelines from the National
Heart Foundation and the Cardiac Society of Australia
and New Zealand have set a threshold for low HDL as
< 1.0 mmol/L [17].
Multiple reports describe extremely low HDL-C levels
in Australian Indigenous populations [8,9,20-25]. In
1979 very low mean HDL-C levels (0.85 mmol/L) were
reported from a small, rural- Western Australian cohort
of young Aboriginal men (<35 years of age) [26] and
from a rural community in central Australia, where
mean HDL-C levels decreased over an eight year period
as obesity and diabetes prevalence increased [22]. Using
the same criteria, a recent report determined low HDL-
C prevalence in a national Indigenous cohort as 70.2%
[27]. Moreover, low HDL-C is not confined to adults: by
the National Cholesterol Education Program Adult Treat-
ment Panel III (NCEP ATP-III) definition of < 40 mg/dL(<1.04 mmol/L), low HDL-C was evident in 30% of Indi-
genous children/adolescents (9–14 years) from Northern
Australia [28]. Crucially, in a 2004 study of 913 partici-
pants from Aboriginal communities in central and north-
ern Australia, 95% of women and 89% of men were found
with low HDL-C (<1.0 mmol/L) a problem apparent even
among those individuals who were lean and without other
abnormalities indicative of MetS [29].
Given the consistency in reports of low HDL-C in
Australian Indigenous people, we sought to establish
whether these findings could be generalized across popu-
lations and settings. Our aims were to: 1) collate and
summarize published data reporting mean HDL-C levels
for both females and males; and 2) where possible, analyze




We use the term ‘Indigenous Australians’ to refer to indi-
viduals identifying as ‘Aboriginal’ or ‘Torres Strait Islander’.
Study locations (e.g. remote, urban) were defined as
described within each study.
Search strategy
Using a multi-field search we conducted a search in the
PubMed, MEDLINE (Web of Knowledge), and Informit









Truncation of terms captured any variation in termin-
ology. Studies retrieved were restricted to full-article,
English-language publications published between Janu-
ary 1950 and January 2012. Additional data sources were
obtained by hand search. Narrative reviews, editorials,
letters, commentaries and grey literature (to ensure in-
clusion of only reliable, peer-reviewed data) were ex-
cluded. Two investigators (JGL and KZW) conducted
the literature searches independently and results were
combined.
Study inclusion criteria
Published original quantitative studies were included for
review if they fulfilled the following selection criteria:
1. The study was based solely on Australian Indigenous
populations, or provided a separate analysis of
Indigenous participants
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of serum or plasma HDL-C levels were reported
separately for males and females.
As there is no single standard for low HDL-C, the pres-
entation of mean HDL-C values rather than prevalence
rates for low HDL-C were used as an inclusion criterion.
We defined low HDL-C as <1.00 mmol/L, as per Australian
clinical guidelines [17]. For all included studies, we required
presentation of both male and female values for HDL-C
in order to examine gender differences and calculate the
female:male HDL-C ratio [12].
Data extraction/study quality assessment
Summary data for included studies were extracted into a
standardized tool that included: citation, study population,
year(s) of study, region (national, urban, rural/regional or
remote), mean sample age/age range, sample size, re-
sponse rate, mean HDL-C levels, and method of HDL-C
measurement. Where possible, the following outcomes
were also extracted as mean values: sex-specific anthropo-
metric measurements (body mass index [BMI], waist cir-
cumference [WC], waist-to-hip ratio [WHR]), age, plasma
C-reactive protein (CRP)) plus prevalence rates for dia-
betes, obesity, current tobacco smoking or infectious dis-
ease states. If multiple reports were available for a given
study, the most recently published report or the report
that provided more comprehensive results was selected
for review. The quality of each study was assessed accord-
ing to study-specific criteria (Table 1), based on previous
general recommendations [30]. Each criterion contributed
two points to an overall score of 10. A score of 10 points
was considered very high quality; 8–9 high quality; 7–6
moderate quality; and < 5 low quality. Different surveys
reported in a single study [22] were assessed separately.
HDL-C data from the 2000 AusDiab study [31] - a national
randomized cluster study- provided the non-Indigenous,
Australian population reference. To examine possible asso-
ciations, mean values of various CVD risk factors obtained
from study results were plotted as independent variables
against mean HDL-C levels, with each sex-specific value
aggregated for each analysis between HDL-C and other var-
iables: mean BMI, WC, WHR, age, CRP and prevalence ofTable 1 Study quality assessment tool
Study quality criteria Example of high score
Selection criteria used Appropriate inclusion/exclusion criteria;
Measurement of study variables Validated method for lipid measuremen
Design specific sources of bias Identification and selection of participan
Use of appropriate statistics Primary analysis of effect and control of
Possible sources of bias Statement of funding sources, conflict o
Legend:
Each criterion was assessed as either high or low score.current smoking and obesity. The degree of association
was assessed by Pearson’s correlation.
Results
Overall 93 articles were obtained in the initial literature
search while another four were retrieved by hand-search.
After evaluation, 15 studies were included for further
qualitative and quantitative analysis (Figure 1). Their
review was undertaken according to PRISMA guidelines
for systematic reviews (see checklist, Additional file 1).
Most included studies were of either high (41%) or
moderate quality (59%)- none were of very high or of low
quality. All were cross-sectional assessments taken at a
single time point, except one [22], where three sequential
cross-sectional surveys were undertaken across a single
community (1987, 1991 and 1995). Here, because reten-
tion rates varied across sex and age group, and cases were
not matched across time points; data from each year were
extracted and presented separately.
Sample sizes varied in size and location (Table 2), from
n = 51, (the adult population in a remote community in
Western Australia [9]) to n = 1641 (23 communities in
far north Queensland [32]). Most studies had a strong
regional focus; 8 of 15 were conducted in single rural or
remote communities in the Northern Territory. One
national survey included participants from medical prac-
tices in capital cities and from remote communities [33]
and two urban surveys were carried out in metropolitan
capital cities [34,35]. Six of the 15 studies presented
HDL-C data in separate groups according to age, but
where a mean overall age was reported, this ranged only
between 29.9-40 years, for both males and females.
While one study included certain paediatric data [9],
data examined here concern only those aged over
15 years.
Women were often overrepresented. Only three stud-
ies had fewer females than males: 39% [9]; 48% [36]; and
49% [32], while in all other studies the proportion of
females ranged from 54-86%. Although some study
response rates were low (down to 14%) [34,35], six of 15
studies reported response rates ≥ 80% [9,23,33,37-39]
and one study reported response rates of between 57-
97%, depending on survey year [22]. Two studies did notlow response rates kept to a minimum or possible explanations provided
t; patient self-reports validated against appropriate existing records
ts limited (e.g. only diabetic patients)
confounding in analyses
f interest
Figure 1 Literature search strategy (PRISMA flowchart).
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retrieved from medical records so that a community re-
sponse rate was not applicable [33]. Another study reported
male and female response rates separately; these varied
from 53% (males, 1995) to 96% (females, 1989) [22]. In-
cluded studies were conducted between 1987-2008.
In total, included studies reported 58 sets of HDL-C
observations (29 for each gender). Mean HDL-C varied
across studies (Figure 2: male [A] and female [B]). The
lowest mean HDL-C reported was from a rural commu-
nity in the Northern Territory, where mean HDL-C was
0.76 mmol/L in males aged < 35 years (1991 survey) and
0.81 mmol/L in females aged 15–24 years (1995 survey)
[22]. This contrasts with results from a 1987–88 studyin regional Victoria, where the highest mean HDL-C levels
were reported: 1.6 mmol/L in men and 1.5 mmol/L
in women [39]. Indeed, only two studies noted such
high mean HDL-C values for men exceeding the mean
value from non-Indigenous reference populations of
1.27 mmol/L [31]: 1.60 mmol/L [39] or 1.38 mmol/L [37].
In females, no other studies found mean HDL-C values
above the non-Indigenous reference (1.57 mmol/L [31]).
Eleven of fifteen studies did not report whether gender
differences in HDL-C levels were of significance. Of the
four that made this analysis, two studies found no sig-
nificant difference [8,37] and one reported significantly
lower HDL-C levels in females [20]. The fourth study
found Aboriginal women to have significantly higher








[33] 2007-08 National survey3 NSW, QLD, Central Australia No No
[35] 2003-05 Urban survey from one metropolis4 NT No6 No
Australian Aboriginal populations
[37] 1986 1 remote community NT No No
[38] 1987 1 remote community NT No No
[39] 1987-88 1 regional community VIC No No
[9] ≈ 1995 1 remote community, Great Sandy Desert WA Both genders
[23] 1988 1 remote community, homeland residences NT Both genders6
[22] 1987 1 rural community NT No No
1991 Both genders7
1995 Both genders7
[21] 1996 1 remote community NT Both genders
[8] 1999-2000 1 remote community, East Arnhem Land NT No Yes
[36] 1992-95 1 remote community, Tiwi Islands NT No No
[20] 2001-03 1 remote community, East Arnhem Land NT No Yes
[34] 2000 Urban study, one metropolis WA No No
[24] 1993-95 11 remote communities, NT, far-north QLD No7 No
[32] 1999-2000 23 rural communities Far-north QLD No7 No
Torres Strait Islander populations
[24] 1993-95 11 remote communities NT, far-north QLD No7 No
[32] 1999-2000 23 rural communities Far-north QLD No7 No
Legend:
1Ethnicity is reported as defined in the original study.
2Low HDL-C defined as mean HDL-C value < 1.00 mmol/L.
390%AA, 9% TSI, 1% both AA and TSI.
484% AA; 6% TSI; 11% both.
6HDL-C levels stratified by age: 15–34 yrs and >35 yrs of age. In both age groups, results were the same.
7HDL-C levels stratified by age into: 15–24 yrs, 25–34 yrs and >35 yrs of age. For all age groups, results are the same.
Abbreviations: HDL-C high-density lipoprotein cholesterol, AA Aboriginal ethnicity, TSI Torres Strait Islander ethnicity, NSW New South Wales, QLD Queensland,
NT Northern Territory, VIC Victoria, WA Western Australia.
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HDL-C between genders was found among Torres Strait
Islanders [24].
While there were no clear gradients in HDL-C accor-
ding to region, Figure 2 shows that low levels of HDL-C
generally predominated in rural and remote-dwelling Indi-
genous populations. This pattern is confirmed in collated
study data (Table 2): all studies reporting low HDL-C in
both males and females were conducted in remote or rural
areas. This contrasts with the national AusDiab cohort, in
which mean HDL-C was not low in either gender. Data
from urban metropolitan areas were also consistent; nei-
ther the study from Darwin, Northern Territory [35], nor
that from Perth, Western Australia [34], showed low mean
HDL-C for males or females. Both these studies however,were subject to low response rates: 14% and 5-20% (de-
pending on age group), respectively. Only two studies
reported HDL-C values specifically for Torres Strait
Islander populations, and neither showed low mean
HDL-C [24,32].
Laboratory methods of HDL-C measurement are detailed
in Additional file 2. The majority of studies report stan-
dardized, full or partially automated techniques, whereas
HDL-C isolation or precipitation was carried out in only
four studies. One study did not state method of HDL-C
measurement [36], and in another, varied methods were
likely, subject to the practice at each medical service from
which medical record data were obtained [33].
Female:male HDL-C ratios are described in Additional
file 2. One third of measurements (10 of 29 pairs in total)
Figure 2 Mean high-density lipoprotein cholesterol (HDL) levels in [A] males and [B] females, according to region. The reference value
was taken from a national survey of non-Indigenous Australians [31]. Each bar represents a single measurement; some studies have reported ≥2
values owing to stratification by ethnicity [24,32], age group [22,23,35,37,38] or year of survey [22].
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males (i.e. ratio < 1.0), which contrasts with the ratio of
1.27 seen in the non-Indigenous reference population
[31]. Overall, the lowest female:male ratios observed were
in rural/regional and remote settings.
Using data available from included studies, mean HDL-C
values were negatively associated with prevalence of dia-
betes, mean WHR and mean/median plasma levels of
CRP (Figure 3). Effect modification by gender was also
observed for each of these variables. Diabetes preva-
lence was significantly inversely associated with HDL-C
levels in males (r = −.373, P = 0.046) but not females
(r = −.314, P = 0.1). Similarly, CRP levels were significantly
associated with HDL-C levels in males (r = −.910, P =
0.03), but not females (r = −.728, P = 0.16) whereas WHR
was significantly associated with HDL-C in females (r =
−.428, P = 0.047) but not males (r = −.288, P = 0.19). Mean
BMI, WC, age and prevalence of current smoking and
obesity did not provide evidence of significant relation-
ships with HDL-C levels in either sex-specific or com-
bined correlation analyses (all P > 0.4).Discussion
Our analysis presents collated evidence of low HDL-C
as a striking CVD risk factor in Aboriginal and Torres
Strait Islander populations. While Indigenous Australians
do not constitute a homogeneous group with respect to
low HDL-C dyslipidemia, very low HDL-C appears par-
ticularly prevalent in rural and remote communities.
Diabetes prevalence is high in Indigenous populations
[40]. Thus co-morbidities of diabetes and the MetS are
likely to be strongly contributing, if not directly causal,
factors in the presentation of low HDL-C. In reports
from which we could source data, we found negative as-
sociations between mean HDL-C levels and diabetes
prevalence, WHR and CRP levels, all well-recognised
CVD risk factors in Indigenous communities [8,41-44].
In remote communities, where we found the lowest
HDL-C levels, poor nutrition, excessive smoking and a
sedentary lifestyle have been well documented. In turn,
these factors are known to contribute to elevated plasma
levels of the inflammatory marker CRP [45], which we
found negatively associated with HDL-C. Although other
Figure 3 Relationships between mean high-density lipoprotein
(HDL) cholesterol levels and selected cardiovascular risk factors:
Diabetes prevalence (%) [A]; Waist-to-hip ratio [B]; Plasma
C-Reactive Protein (mg/dL) [C].
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tions such as smoking and renal disease [2] were prominent
in our included studies they failed to impact on HDL-C in
our pooled analyses.
Some populations in rural/regional and remote/isolated
locations did not exhibit low HDL-C levels [32,37,38].
Two factors: absence of obesity and high alcohol intake
may explain this. One of these studies came from an
isolated non-obese community, where mean BMIs were
20.4-23.5 kg/m2 [37]. Similarly, whereas an initial cross-
sectional study from a rural community in the Northern
Territory, reported high mean HDL-C levels, a subsequent
survey 8 years later, indicated both significant weight gain,
and a reduction in HDL-C levels [22]. Secondly, alcohol
consumption may be critical; a study conducted in a small
isolated community in the Northern Territory, found that
‘drinking’ (defined as those who consumed any alcohol)
reduced the risk of low HDL-C (odds ratio: 0.4, 95% CI
0.2-0.6) [46]. The contribution of alcohol consumption to
higher HDL-C in some populations is also suggested by
some studies in remote locations [37-39]. In addition in
one large study across 23 rural communities, where higher
HDL-C levels were evident the prevalence of ‘drinking’
ranged from 51%-82% [32]. Also, Guest et al. acknowledge
that alcohol consumption may have influenced the high
HDL-C levels seen in another regional population [39].
The preponderance of studies undertaken in rural/re-
mote settings was a prominent finding, typical of broader
Indigenous health research [47]. Owing to the sampling
method of AusDiab, which excluded districts if they were
classified 100% rural [48], we could not directly compare
HDL-C levels between Indigenous and non-Indigenous
populations by location. However, in a population survey
conducted wholly in non-indigenous rural populations in
south-eastern Australia, mean HDL-C levels reported
were 1.59 mmol/L for women and 1.33 mmol/L for men
[49]. These levels are comparable to the AusDiab cohort,
and much higher than in Indigenous populations from
rural areas included in this review.
Low HDL-C dyslipidaemia clearly results from a com-
plex interplay of environmental and genetic factors [50]
with heritability estimated at 40-80% [51]. Indeed, the
Turkish Heart Study found that high prevalence of low
HDL-C (70% of men, 50% of women) could be attrib-
uted to a 25-30% higher hepatic lipase activity, suggest-
ing a strong genetic component [52]. Few data however
are available to link genetic predisposition to low HDL-
C levels in Australian Indigenous populations. One early
study found that 26% of a small population from the
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ried the ε4 allele for the APOE gene, known to be asso-
ciated with raised plasma cholesterol and higher risk of
CVD [53]. Furthermore, in a medium-sized study (n =
155) in southeast Queensland, APOE4 polymorphisms
were 1.8 times more prevalent in Indigenous than non-
Indigenous participants and associated with high triglycer-
ides and low HDL-C [54]. Thus genetic differences cannot
be unequivocally excluded as possible contributors to dif-
fering HDL-C phenotype across our study settings, while
genetic admixture may contribute to the higher HDL-C
observed in urban areas [34,35]. One exception here is a
small, early study from northern Western Australia, where
urban Aboriginal men had higher HDL-C levels than rural
men. As both groups were identified as ‘full-blood Abori-
ginal’, factors such as urbanization and higher alcohol
consumption may have been critical modifiers of lipid
levels [26]. Early life epigenetic modifications may also
potentially impact on HDL-C levels [55]. Nevertheless, the
body of evidence is clear: non-genetic and modifiable
influences appear critically important in the development
of low HDL-C dyslipidemia.
Although studies in predominantly North American
and western European populations indicate that women
have higher HDL-C levels than men, data collated here
from rural and remote Indigenous communities indicate
this is not necessarily always the case. Different popula-
tions display different magnitudes in these sex differ-
ences [56]. Other populations of impoverished people
(including rural poor in Andhra Pradesh, southern India
[57]; Indigenous tribes in Himalayan India [58]), and
Indigenous populations undergoing rapid epidemiologic
transition in northern Russia, show similar low HDL-C
levels in both women and men [59].
As a clinical consequence of a high burden of disease,
low HDL-C in the Australian Indigenous population ap-
pears intrinsically linked to adverse socio-demographic
determinants driving the high rate of poor health (e.g.:
education, occupation and income) [60]. Both acute in-
fection and chronic inflammation reduce HDL-C levels
[13]. Infection/chronic inflammation are common in In-
digenous Australians, particularly those from remote
areas, where parasitic, fungal, viral and bacterial infec-
tions are promoted by poor household infrastructure,
overcrowding and overdue vaccinations [61]. Accord-
ingly, high CRP levels are a common CVD risk factor
[41,44]. Communicable disease appears to be a poten-
tially important contributor to the highly prevalent low
HDL-C and high CRP reported here as evidenced by the
negative association we found between mean CRP and
mean HDL-C levels. This is consistent with other data
[8,21] in Indigenous populations, including inverse associ-
ations seen between HDL-C levels and other atherogenic
biomarkers such as vascular cell adhesion molecules [21]and fibrinogen [8,24]. One small, prospective epidemio-
logical study of critical care patients in central Australia
found that despite similar low HDL-C levels upon ad-
mission, HDL-C levels only remained low six months
after discharge in the Indigenous group (median HDL-C:
0.8 mmol/L vs. 1.5 mmol/L in non-indigenous patients)
[62]. Also, erythrocyte sedimentation rate, a marker of
chronic inflammation, was significantly higher in the
Indigenous patients at follow-up. Significantly, pro-
atherogenic changes to HDL-C during states of infection/
inflammation may accelerate CVD risk, beyond the risk
conveyed by low HDL-C per se [13].
Our study has some limitations. Due to the small
number of often cluster-based studies, external validity
with respect to the wider or national Indigenous popula-
tion in Australia must be uncertain. Nevertheless, we are
confident that we give an accurate representation of low
HDL-C prevalence in rural and remote communities.
One potential source of bias is the variety of methods
used to determine HDL-C especially in earlier studies
(1980s-90s), although over the last 15 years methodology
has been largely consistent. Studies providing only per-
centage prevalence of low HDL-C at different thresholds
were excluded. Although their inclusion would expand
the evidence base, it does not aid in finding an estimate
of the prevalence of low HDL-C.
Associations about the impact of traditional CVD risk/
‘lifestyle’ factors on the presentation of low HDL-C are
now well recognized. However, research of lipid-specific
metabolic dysfunction is likely to provide further insight
into the extent it contributes to CVD risk in such high-
burden populations. O’Neal et al. [25] identified a particu-
larly atherogenic lipid profile in Aboriginal communities
across northern Australia, that was characterized not only
by low HDL-C, but also by an increase in small, dense
LDL particles known to be highly susceptible to oxidative
modification. Dysfunctional changes to lipoprotein compos-
ition may also be occurring for HDL as for LDL particles.
For example, examination of the role of apolipoprotein-A1,
which governs the ability of HDL to perform reverse choles-
terol transport, would be valuable in assessing the relative
importance of particle number, HDL-C content and func-
tion on CVD risk in Australian Indigenous populations.
Examination of relationships between HDL-C and infec-
tious disease load in these populations would also be valu-
able. If confirmed, these features together represent a very
high-risk cardio-metabolic profile and may go some part
in explaining the excess CVD morbidity and mortality that
exists in Indigenous populations.
Conclusions
This review confirms that low HDL-C levels are com-
mon in Australia’s Indigenous populations, and predom-
inate in rural and remote locations. Associations found
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are also widespread in these communities provide aggre-
gated evidence linking HDL-C and other features of
cardio-metabolic risk, including a relationship between
HDL-C and the inflammatory marker CRP. Such interre-
lationships provide a compelling case in support of
comprehensive preventive health programs to reduce the
burden of both communicable and non-communicable
disease in Indigenous populations.
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